Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Prashan Thiagarajah

Internal Medicine Pittsburgh, PA Medical Doctor

NPI 1184924417 CMS profile 54281

3601 McKnight East Dr, Pittsburgh, PA 15237

Open in the dashboard

General payments

$18,858

1,214 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Prashan Thiagarajah of Pittsburgh, PA is reported in the CMS Open Payments database as having received $18,858 across 1,214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,584 139
2024 General $3,137 200
2023 General $3,185 208
2022 General $2,836 203
2021 General $3,196 196
2020 General $2,284 153
2019 General $1,637 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Prashan Thiagarajah
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Prashan Thiagarajah were reported at $2,584. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Prashan Thiagarajah Internal Medicine median Middle half National median
2019 $1,637 $159 $48–$570 $163
2020 $2,284 $119 $33–$402 $114
2021 $3,196 $135 $37–$521 $132
2022 $2,836 $141 $42–$496 $149
2023 $3,185 $149 $45–$519 $160
2024 $3,137 $154 $47–$537 $164
2025 $2,584 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,861 223 payments
  2. AbbVie, Inc. $2,139 156 payments
  3. Janssen Pharmaceuticals, Inc $1,615 86 payments
  4. AstraZeneca Pharmaceuticals LP $1,573 86 payments
  5. GlaxoSmithKline, LLC. $1,107 79 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $1,094 65 payments
  7. Amgen Inc. $1,008 58 payments
  8. Pfizer Inc. $844 72 payments
  9. Lilly USA, LLC $617 37 payments
  10. Abbott Laboratories $429 30 payments
  11. Other $5,571 322 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,780 1,210 payments
  2. Gift $47 1 payment
  3. Education $31 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,830 146 payments
  2. RYBELSUS $1,523 120 payments
  3. XARELTO $1,131 65 payments
  4. UBRELVY $1,099 83 payments
  5. FARXIGA $1,071 54 payments
  6. TRELEGY ELLIPTA $815 60 payments
  7. JARDIANCE $588 31 payments
  8. Repatha $579 33 payments
  9. VRAYLAR $563 40 payments
  10. Saxenda $506 33 payments
  11. Other $15,538 968 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 136 drugs

Part D claims

7,130

Median for Internal Medicine: 777

Drug cost

$657,647

Median for Internal Medicine: $73,373

Branded share of claims

21.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 132 $158,374
Eliquis Apixaban Brand 130 $123,788
Xarelto Rivaroxaban Brand 46 $44,155
Farxiga Dapagliflozin Propanediol Brand 45 $37,083
Repatha Sureclick Evolocumab Brand 53 $34,431
Trulicity Dulaglutide Brand 25 $34,240
Jardiance Empagliflozin Brand 23 $29,670
Mounjaro Tirzepatide Brand 24 $28,542
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 33 $28,272
Entresto Sacubitril/Valsartan Brand 18 $20,240

The 10 drugs with the highest cost, of 136 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$136,269

Of which drugs: $14,386

Medicare patients

346

Average age 73

Services billed

3,454

168 women, 178 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Depression 38%
Diabetes 36%
Ischemic heart disease 32%
Chronic kidney disease 32%
Atrial fibrillation 22%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 26 26 $7,539
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 26 26 $2,046
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 140 $110

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 54 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$176 — —
Ozempic
$150 132 —
SPRAVATO
$150 — —
FARXIGA
$131 45 —
BREZTRI
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 54 with Patron

Records

1,214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record